Efficacy Of Erythromycin Phonophoresis on Chronic Rhinosinusitis
1 other identifier
interventional
90
1 country
1
Brief Summary
The purpose of the study is to evaluate the therapeutic effect of erythromycin phonophoresis in reducing chronic rhinosinusitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2025
CompletedStudy Start
First participant enrolled
July 7, 2025
CompletedFirst Posted
Study publicly available on registry
July 14, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 7, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 15, 2025
CompletedJuly 14, 2025
July 1, 2025
2 months
May 30, 2025
July 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sinusitis symptom score (SSS)
Sinusitis Symptom Scores will be based on a visual analogue scale (VAS) well established. In this method, the six symptoms will be assessed using a scale of 0±10, where zero represents no symptom and 10 represents the most severe symptom imaginable
one month
Secondary Outcomes (1)
Computerized tomography scan (CTS)
one month
Study Arms (3)
Erythromycin Phonophoresis + Medical treatment
EXPERIMENTALThis group will include 30 patients with chronic rhinosinusitis who will receive Erythromycin phonophoresis 12 session, 3 days per week, and medical treatment (saline nasal wash) 3 times daily for a month.
Ultrasound + Topical Erythromycin + Medical treatment
ACTIVE COMPARATORThis group will include 30 patients with chronic rhinosinusitis who will receive ultrasound followed by topical use of Erythromycin gel on nose 12 session , 3 days per week and medical treatment (saline nasal wash) 3 times daily for a month.
Medical treatment
OTHERThis group includes 30 patients with chronic rhinosinusitis who will receive their medical treatment (saline nasal wash) 3 times daily for a month
Interventions
The procedures of ultrasound phonophoresis will be as follows: Patients will be positioned comfortably, sitting in a relaxed position. The physiotherapist will explain the treatment procedures to the patient. The device cables will be checked before each session. The treatment will last 5 minutes for each maxillary sinus. The frequency will be set to 1 MHz, and the intensity will be 1 W/Cm2 for the maxillary sinuses. The ultrasound will be pulsed, and the treatment will consist of 12 sessions, 3 days per week.
Therapeutic US is produced by a transducer composed of a piezoelectric crystal, which converts electric energy into alternating compression and rarefaction of sound waves at a frequency greater than 20 kHz. The amplitude of the US wave is proportional to the displacement of the US transducer head during each half cycle. The amplitude represents the wave energy. The ultrasound waves penetrate the tissue on the way to the target organ and have two mechanisms of action (thermal and non-thermal), which may potentially work synergistically to reduce nasal symptoms (nasal blockage and secretions).
Erythromycin is a 14-member macrolide originally discovered in the 1950s. It has broad-spectrum antimicrobial action, inhibiting bacterial protein synthesis. studies have shown that erythromycin has immunomodulatory and anti-inflammatory activity independent of its antimicrobial action Erythromycin is a broad-spectrum macrolide antibiotic, wherein its bactericidal effect occurs by the inhibition of protein synthesis. It is used for the treatment of infections affecting the skin and mucosa; it shows immunomodulatory characteristics
Saline nasal wash 3 times daily for a month.
Eligibility Criteria
You may qualify if:
- Age range between 25-50 years.
- Male and female patients will participate in the study.
- All patients have chronic rhinosinusitis.
- All patients enrolled in the study will have their informed consent.
- CT will include at least affection of maxillary sinus.
You may not qualify if:
- Patients with pacemaker
- Patients diagnosed with cancer.
- Pregnant women
- Patients with impaired vascular circulation
- Patients who suffer from mental or psychological disorders.
- Patients with any systemic diseases that may interfere with the objectives of the study.
- Congenital defects on face and nose.
- Fracture of nose or face.
- Polypoidal patients.
- Allergic patients.
- Previous nasal surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Alexanderia Police Hospital
Alexandria, Egypt
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nahla Mahmoud Elkassas, B.Sc
Physotherapist at Alexanderia Police Hospital
- STUDY CHAIR
Hussein Gamal Hussein Mogahed, PhD
Assistant Professor, Cairo university
- STUDY DIRECTOR
Mustafa Mohamed Abdelnaby, PhD
Assistant Professor, Alexandria university
- STUDY DIRECTOR
Aya Gamal Fawzy Elsayed, PhD
Lecturer, Cairo university
Central Study Contacts
Aya Gamal Fawzy Elsayed, PhD
CONTACT
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 30, 2025
First Posted
July 14, 2025
Study Start
July 7, 2025
Primary Completion
September 7, 2025
Study Completion
September 15, 2025
Last Updated
July 14, 2025
Record last verified: 2025-07